Claritev Corporation CTEV R2KPHARMA
Company Overview
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services. It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $965.41M (+3.7% YoY); net profit $-284.28M.
- Trailing 12 Months Year-on-year growth — revenue +6.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.07% |
| 1 Year: | 6.60% |
Stock Price Performance
| 1 Year: | -66.61% |
| 6 Months: | -1.30% |
| 3 Months: | +7.70% |
| 1 Month: | +0.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -1.1% CAGR over 5 years.
- Trading 67.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CTEV Claritev Corporation R2KPHARMA | 23.50 | -1.38 | $398.27M | 0.00% | 0.62% | - | -1.07% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 245.02M | 245.65M | 245.82M | 246.40M | 252.02M | 206.88M | 223.52M | 255.34M | 254.86M | 276.27M | 288.21M | 298.05M | 290.13M | 250.45M | 236.59M | 237.99M | 242.80M | 234.51M | 233.48M | - | - | 231.33M | 241.57M | 245.96M | 246.55M | 244.68M | 257.48M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.20M | 79.13M | 82.31M | 78.03M | 80.81M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.13M | 162.44M | 163.65M | 168.52M | 163.87M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 140.72M | 145.86M | 153.59M | 159.85M | 157.19M | - |
| Operating Income | 85.10M | 99.32M | 81.11M | 102.68M | 87.62M | 20.27M | -199.50M | -40.20M | 82.27M | 89.80M | 104.45M | 116.64M | 97.77M | 36.40M | 46.94M | 34.71M | 39.52M | -486.44M | -523.93M | - | - | 13.41M | 16.58M | 10.07M | 8.67M | 6.68M | 23.41M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 113.31M | 128.83M | 120.49M | 104.77M | 118.47M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 91.64M | 99.75M | 101.23M | 99.41M | 99.54M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -89.87M | -82.93M | -93.36M | -106.92M | -92.72M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.55M | -20.29M | -23.61M | -26.35M | -19.16M | - |
| Net Income | -8.36M | 868.00K | 5.36M | 11.84M | -2.59M | -56.25M | -288.40M | -173.32M | 45.88M | -46.93M | 78.20M | 43.98M | 13.51M | 19.74M | 209.00K | -36.37M | -24.14M | -539.69M | -576.73M | - | - | -71.32M | -62.64M | -69.75M | -80.57M | -73.56M | -59.23M |
| Diluted EPS | - | - | - | - | -0.01 | -0.14 | -0.69 | - | 0.07 | -0.07 | 0.12 | 0.07 | 0.02 | 0.03 | 0.00 | -0.06 | -1.49 | -33.40 | -35.78 | - | - | -4.38 | -3.81 | -4.23 | -4.88 | -4.41 | -3.49 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04B | 982.90M | 937.76M | 1.12B | 1.08B | 961.52M | 930.62M | 965.41M |
| Operating Income | 427.54M | 368.21M | -131.82M | 386.12M | -362.73M | 161.98M | -1.39B | 28.77M |
| Net Income | 36.22M | 9.71M | -520.56M | 102.08M | -572.91M | -91.70M | -1.65B | -284.28M |
| Diluted EPS | - | 0.02 | -1.11 | 0.16 | -0.90 | -5.69 | -101.92 | -17.30 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 8.36B | 8.28B | - | 7.37B | 6.96B | 5.15B | 4.89B |
| Current Assets | - | - | - | - | - | 446.74M | 193.59M | 175.51M | 224.37M |
| Cash & Equivalents | - | - | 21.82M | 126.75M | - | 334.05M | 71.55M | 16.85M | 16.81M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 78.91M | 76.56M | 89.76M | 127.61M |
| Total Liabilities | - | - | 6.38B | 5.73B | - | 5.58B | 5.26B | 5.07B | 5.06B |
| Current Liabilities | - | - | 85.79M | 112.50M | - | 175.84M | 166.74M | 213.79M | 261.36M |
| Long Term Debt | - | - | - | - | - | 4.74B | 4.53B | 4.51B | 4.58B |
| Total Debt | - | - | - | - | - | 4.78B | 4.57B | 4.54B | 4.62B |
| Total Equity | 1.95B | 1.99B | 1.99B | 2.56B | - | 1.79B | 1.71B | 84.02M | -173.90M |
| Shares Outstanding | - | - | - | - | - | 16.66M | 16.70M | 16.93M | 17.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 292.30M | 284.31M | 377.37M | 404.69M | 372.36M | 171.72M | 107.62M | 117.32M |
| Investing Cash Flow | -63.56M | -66.41M | -210.84M | -228.38M | -104.45M | -249.79M | -118.12M | -121.02M |
| Financing Cash Flow | -245.15M | -201.09M | -61.60M | -114.68M | -115.74M | -180.99M | -41.31M | 2.36M |
| Capital Expenditure | -63.56M | -66.41M | -70.81M | -84.59M | -89.73M | -108.85M | -118.12M | -129.60M |
| Free Cash Flow | 228.75M | 217.90M | 306.56M | 320.10M | 282.63M | 62.87M | -10.51M | -12.28M |
| Share Buybacks | 0 | 0 | 101.12M | 100.00M | 0 | 15.22M | 10.37M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | 41.1% | 37.5% | -14.1% | 34.5% | -33.6% | 16.8% | -149.4% | 3.0% |
| Net Margin % | 3.5% | 1.0% | -55.5% | 9.1% | -53.1% | -9.5% | -176.9% | -29.4% |
| ROE % | 1.8% | 0.5% | -20.4% | - | -32.0% | -5.4% | -1,958.8% | 163.5% |
| ROCE % | - | 4.4% | -1.6% | - | -5.0% | 2.4% | -28.2% | 0.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | H&F Corporate Investors VIII, Ltd. | 22.94% | 3.89M | $95.87M |
| 2 | Ares Management LLC | 10.99% | 1.86M | $45.94M |
| 3 | Arini Capital Management Ltd | 9.06% | 1.53M | $37.85M |
| 4 | Public Investment Fund | 7.56% | 1.28M | $31.60M |
| 5 | Beach Point Capital Management LP | 4.55% | 770.61K | $19.00M |
| 6 | Blackrock Inc. | 4.27% | 723.22K | $17.83M |
| 7 | CPV Partners, LLC | 2.92% | 495.26K | $12.21M |
| 8 | Vanguard Capital Management LLC | 2.50% | 423.04K | $10.43M |
| 9 | Prudential Financial, Inc. | 2.09% | 353.90K | $8.73M |
| 10 | Geode Capital Management, LLC | 1.33% | 225.15K | $5.55M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTEV
CTEV Nov 2026 25.000 call (CTEV261120C00025000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE8zTWdwbGczQm1QZHZHSFBvM2VSUlRxYkNycXRRSm14X19TVnpmLXhfM1V0R011UFNfUHJNSURLZnNrSlBmUkhWejZWakdtek5RQnoyck5Yb0RZTXUtdWhpeHRpNW5PQQ?oc=5" target="_blank">CTEV Nov 2026 25.000 call (CT…
A director's pro-rata stock grant brings her direct holding in Claritev (CTEV) to 3,113 shares. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNlA1bkswSGZvb0pDYS1WS3N2d0pVNXY1dGlqS1JmaTM3MFBwUUdkU2xkS0pkaHBhMTBLWHVVcHlBWlVwM0ZSSGtleXQ3RXdreE1Sbm5DME9raDdKM1pRUVRGbHhLS19UVmRYdFMyejJUYllZMVdYMm9JazM4MW5rOU51SkhKVnpxWFJpZT…
Claritev (NYSE:CTEV) Slides Premarket Despite Q1 Revenue Beat as Net Loss Widens - ChartMill
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNclkyS25VcGpFVUVxa01SSXlPZlkxUzlOUVpXU2N1YTdULWxKaWgyV0tzWnA4V3huODAwN0VSdU40Sk04SHlXVUtQMG82U3J2clpfUkdBUjlydFBpZUpqZHI4V0NTRU5vZTI4YmM5Skx6d1JGNlhPemg1bFJnem9mXy1iaVMzNWgtZUF2N1…
Claritev (CTEV) Stock Faces Mixed Analyst Target Changes As Growth Execution Questions Build - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNNXdUMnJMeEt6WlVINVZsU25NeThPVnJ5UGo2bHYzeElfdEd1ZXpZa09xNkRwZlpWRzlRQU1xb3UtMUJ5QjVaUXdSM1MwSXdDZW10UDlsNWN0eFp5eTFKeUJNNDRjVHdqX2VvQ0ZWZERxZ0RqRTdaOVRsaUFJNWRjV21pSDVGN1ZoRnJObE…
What Claritev Doubters Saw Before A 65% Fall - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPVjlIZ1VpT0dFNndiZjZPNHlINDFTWGdnRnpjWWJjbS1aaXBKVjlqWlVMcUIwUTVxSEhFbUtOVHdUWHdiejFZQzU1ejdGb2Z0Ynd3ZDRaX2xFUTJ4d3JEb1ZpUDR2ZkY0YmhFNHV1ckZheTZzOWtYNV9Qc3hReXdWZFhTOTZuT1d2eG9PMz…
Claritev: Revenue Growth Is Back, Cash Flow Is The Next Test (NYSE:CTEV) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNbk9tZWs1WWMzYTBQWEw5VUZLWnI3RFlMOElieFJQWGUydjFUSzdvWFFmWU42TXJfMlBMYmpXSjhFN3J3XzI5QlVyT0ZKM3pjeFREeDhTYXBrczBSZ1V2RzNwMlhCVVRjWjFFblpJb3hmTEl0SjEtNHZxbTM3ZUJUYmJnbUZxZDE3VjdTam…
CTEV — Frequently Asked Questions
What is the current share price of Claritev Corporation (CTEV)?
As of 2026-10-23 16:27 PDT, Claritev Corporation (CTEV) trades at $23.50 on NYSE. Its 52-week range is $13.47 to $72.58.
What is the market capitalisation of CTEV?
Claritev Corporation (CTEV) has a market capitalisation of $398.27M on NYSE.
What is the P/E ratio of CTEV?
CTEV trades at a trailing price-to-earnings (P/E) ratio of -1.38. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -1.42.
Is CTEV a good stock to buy?
This page provides a data-driven analysis of Claritev Corporation (CTEV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.